|
⚲
|
| Keyboard |
| IBF Management Ltd
✚
|
|
|---|---|
| CRD # | 283544 |
| SEC # | 802-107705 |
| CIK # | 0001994849 |
| AUM | |
| Employees | |
| Phone | 972722514175 |
| Address | 4 Oppenheimer St Rehovot, Israel |
| Source | [IAPD] [EDGAR] [Website] |
| Total AUM ($) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| VC | Israel Biotech Fund II LP | [2020-03-02] | 25.0 M | |
| Offered $100,000,000 · Filed 2015-10-22 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $100,000,000 · Duration One year or less · Revenue Decline to Disclose | ||||
| VC | Israel Biotech Fund I LP | [2019-02-15] | 25.0 M | |
| Offered $100,000,000 · Filed 2015-10-22 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $100,000,000 · Duration One year or less · Revenue Decline to Disclose | ||||
| VC | Israel Biotech Fund I LP | [2016-04-12] | 25.0 M | |
| Offered $100,000,000 · Filed 2015-10-22 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $100,000,000 · Duration One year or less · Revenue Decline to Disclose | ||||
| AUM Breakdown | Accounts | AUM ($) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 0 | 0.0 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 0 | 0.0 |
| By Discretionary | ||
| Discretionary | 0 | 0.0 |
| Non-Discretionary | 0 | 0.0 |
| Total | 0 | 0.0 |
| By Non-United States Persons | ||
| Non-United States Persons | 0.0 | |
| United States Persons | 0.0 | |
| Total | 0 | 0.0 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| David Sidransky | Executive Officer | 32 | 2 | |
| Yuval Cabilly | Executive Officer | 3 | 2 | |
| Ido Zairi | Executive Officer | 2 | 2 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 4 | [0001994849] |
| Firm Profile (Form ADV) | |
|---|---|
| Fund Types | Private Equity |
| Form 3/4/5 Subject | 2011 - 2026 |
|---|---|
| Israel Biotech Fund I LP | |
| Israel Biotech Fund GP Partners LP | |
| Israel Biotech Fund II LP | |
| IBF Management Ltd | |
| Israel Biotech Fund GP Partners II LP | |
| Ayala Pharmaceuticals Inc |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Ayala Pharmaceuticals Inc ADXS
Rights · derivative
|
2024-03-01 | Option exercise | 3,750,000 | ||
|
Ayala Pharmaceuticals Inc ADXS
Convertible Promissory Note · derivative
|
2024-03-01 | Option exercise | 1,500,000 | ||
|
Ayala Pharmaceuticals Inc ADXS
Warrants · derivative
|
2024-03-01 | Option exercise | 2,250,000 | ||
|
Ayala Pharmaceuticals Inc ADXS
Convertible Promissory Note · derivative
|
2024-03-01 | Option exercise | 1,500,000 | ||
|
Ayala Pharmaceuticals Inc ADXS
Warrants · derivative
|
2024-03-01 | Option exercise | 2,250,000 | ||
|
Ayala Pharmaceuticals Inc ADXS
Rights · derivative
|
2024-03-01 | Option exercise | 3,750,000 | ||
|
Ayala Pharmaceuticals Inc ADXS
Common Stock, par value $0.001 per share
|
2024-02-07 | Option exercise | 8,437,500 | $0.40 | 3,375,000 |
|
Ayala Pharmaceuticals Inc ADXS
Common Stock, par value $0.001 per share
|
2024-02-07 | Option exercise | 4,237,687 | $0.40 | 1,695,075 |
|
Ayala Pharmaceuticals Inc ADXS
Common Stock, par value $0.001 per share
|
2024-02-07 | Option exercise | 3,887,438 | $0.40 | 1,554,975 |
|
Ayala Pharmaceuticals Inc ADXS
Common Stock, par value $0.001 per share
|
2024-02-07 | Tax withheld | 2,586,905 | $1.25 | 3,233,631 |
|
Ayala Pharmaceuticals Inc ADXS
Common Stock, par value $0.001 per share
|
2024-02-07 | Tax withheld | 2,707,581 | $1.25 | 3,384,476 |
|
Ayala Pharmaceuticals Inc ADXS
Common Stock, par value $0.001 per share
|
2024-02-07 | Option exercise | 8,062,500 | $0.40 | 3,225,000 |
|
Ayala Pharmaceuticals Inc ADXS
Common Stock, par value $0.001 per share
|
2024-02-07 | Option exercise | 1,295,813 | $0.40 | 518,325 |
|
Ayala Pharmaceuticals Inc ADXS
Convertible Promissory Note · derivative
|
2024-02-07 | Option exercise | 3,887,438 | ||
|
Ayala Pharmaceuticals Inc ADXS
Warrants · derivative
|
2024-02-07 | Option exercise | 8,062,500 | ||
|
Ayala Pharmaceuticals Inc ADXS
Convertible Promissory Note · derivative
|
2024-02-07 | Option exercise | 1,295,813 | ||
|
Ayala Pharmaceuticals Inc ADXS
Warrants · derivative
|
2024-02-07 | Option exercise | 8,437,500 | ||
|
Ayala Pharmaceuticals Inc ADXS
Convertible Promissory Note · derivative
|
2024-02-07 | Option exercise | 1,926,221 | ||
|
Ayala Pharmaceuticals Inc ADXS
Convertible Promissory Note · derivative
|
2024-02-07 | Option exercise | 4,237,687 | ||
|
Ayala Pharmaceuticals Inc ADXS
Common Stock, par value $0.001 per share
|
2024-02-07 | Option exercise | 1,926,221 | $0.40 | 770,488 |
| showing 20 of 32 most recent transactions | |||||